Experts in breast oncology review 4 clinical cases and discuss individualized treatment approaches for each patient.
EP. 1: Case 1: Early-Stage HER2+ Breast Cancer
Watch
EP. 2: Case 1: Decision Making in Early Stage HER2+ Breast Cancer
EP. 3: Case 1: Guidelines for HER2 Testing in Breast Cancer
EP. 4: Case 1: When to Use FISH Testing in Breast Cancer
EP. 5: Case 1: Clinical Trials in Early-Stage HER2+ Breast Cancer
EP. 6: Case 1: Treatment for Early-Stage HER2+ Breast Cancer
EP. 7: Case 1: Adjuvant Therapy for Residual Disease in HER2+ Breast Cancer
EP. 8: Case 2: ER+ Breast Cancer
EP. 9: Case 2: CDK4/6 Inhibitors in ER+ Breast Cancer
EP. 10: Case 2: Treatment Recommendations for ER+ Breast Cancer
EP. 11: Case 2: Defining Strongly Versus Less Strongly ER+ Breast Cancer
EP. 12: Case 2: CDK4/6 Inhibitor Recommendations in ER+ Breast Cancer
EP. 13: Case 3: Metastatic Triple-Negative Breast Cancer
EP. 14: Case 3: Results of the IMpassion130 Trial in Metastatic Breast Cancer
EP. 15: Case 3: The Use of Combination Therapy in Triple-Negative Breast Cancer
EP. 16: Case 3: PD-L1 Testing Used in Triple-Negative Breast Cancer
EP. 17: Case 3: Managing Immune-Related Adverse Effects in TNBC
EP. 18: Case 3: Treatment After Progression in Triple-Negative Breast Cancer
EP. 19: Case 4: BRCA+ Metastatic Breast Cancer
EP. 20: Case 4: OlympiAD Trial for BRCA+ Metastatic TNBC
EP. 21: Case 4: PARP Inhibitors for Treating BRCA+ Triple-Negative Breast Cancer
EP. 22: Case 4: Chemotherapy or PARP inhibitors for BRCA+ TNBC
EP. 23: Case 1: Approach to Early Stage, HER2+ Breast Cancer
EP. 24: Case 2: Choosing a CDK4/6 Inhibitor in ER+ Breast Cancer
EP. 25: Case 3: Atezolizumab/Nab-Paclitaxel for Triple Negative Breast Cancer
EP. 26: Case 4: Looking Forward in BRCA+ Metastatic TNBC
EP. 27: Balixafortide and Eribulin Shows Modest Responses in Patients with HER2-Negative Breast Cancer
Balixafortide in combination with eribulin did not improve objective response rate compared to eribulin alone for the treatment of HER2-negative, locally recurrent or metastatic breast cancer, missing the coprimary end point of the FORTRESS study.
Read More
